Insights

Recovery potential Sorrento is a clinical stage biopharma with ongoing programs across oncology, autoimmune, infectious diseases and neurodegenerative targets, suggesting cross-industry sales opportunities for collaborations, licensing, or partnerships to leverage their G-MAB library and delivery modalities.

Diversified modality stack Their proprietary modalities including CAR-T, DAR-T, ADCs, oncolytic virus, lymphatic targeting, and bispecific antibodies indicate multiple entry points for co-development, contract manufacturing, or technology licensing with firms seeking advanced biologics capabilities.

COVID and rapid testing focus Active development and clinical studies in coronavirus antivirals, vaccines, and diagnostic solutions (COVISTIX, COVITRACK) create upsell avenues for diagnostic partnerships, assay integration, or joint programs with diagnostic distributors and pharma developers.

Financial restructuring signal Chapter 11 filing and restructuring in 2023 accompanied by ongoing litigation and financing pressures imply caution but also potential distressed asset opportunities, strategic partnerships, or debt-for-equity discussions for interested buyers or investors.

Strategic capabilities fit With a mid-sized employee base and notable tech stack (Salesforce, New Relic, design, modeling, and manufacturing tooling), Sorrento presents opportunities for technology licensing, ERP/CRM optimization partnerships, and clinical data management or digital commercialization collaborations.

Similar companies to Sorrento Therapeutics, Inc.

Sorrento Therapeutics, Inc. Tech Stack

Sorrento Therapeutics, Inc. uses 8 technology products and services including Veeam, AutoCAD, SOLIDWORKS, and more. Explore Sorrento Therapeutics, Inc.'s tech stack below.

Media & News

Sorrento Therapeutics, Inc.'s Email Address Formats

Sorrento Therapeutics, Inc. uses at least 4 email formats:
Sorrento Therapeutics, Inc. Email FormatsExamplePercentage
FLast@sorrentotherapeutics.comJDoe@sorrentotherapeutics.com
93%
F.Last@sorrentotherapeutics.comJ.Doe@sorrentotherapeutics.com
4%
First.Last@sorrentotherapeutics.comJohn.Doe@sorrentotherapeutics.com
2%
FMiddleLast@sorrentotherapeutics.comJMichaelDoe@sorrentotherapeutics.com
1%

Frequently Asked Questions

What is Sorrento Therapeutics, Inc.'s phone number?

Minus sign iconPlus sign icon
You can contact Sorrento Therapeutics, Inc.'s main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Sorrento Therapeutics, Inc.'s stock symbol?

Minus sign iconPlus sign icon
Sorrento Therapeutics, Inc. is a publicly traded company; the company's stock symbol is SRNE.

What is Sorrento Therapeutics, Inc.'s official website and social media links?

Minus sign iconPlus sign icon
Sorrento Therapeutics, Inc.'s official website is sorrentotherapeutics.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does Sorrento Therapeutics, Inc. generate?

Minus sign iconPlus sign icon
As of October 2026, Sorrento Therapeutics, Inc.'s annual revenue is estimated to be $50M - $100M.

What is Sorrento Therapeutics, Inc.'s SIC code and NAICS code?

Minus sign iconPlus sign icon
Sorrento Therapeutics, Inc.'s SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Sorrento Therapeutics, Inc. have currently?

Minus sign iconPlus sign icon
As of October 2026, Sorrento Therapeutics, Inc. has approximately 105 employees across 5 continents, including North America, Europe and Africa. Key team members include Chief Executive Officer: H. J., Chief Executive Officer: H. J. and Chief Executive Officer: H. J. Explore Sorrento Therapeutics, Inc.'s employee directory with LeadIQ.

What industry does Sorrento Therapeutics, Inc. belong to?

Minus sign iconPlus sign icon
Sorrento Therapeutics, Inc. operates in the Biotechnology Research industry.

What technology does Sorrento Therapeutics, Inc. use?

Minus sign iconPlus sign icon
Sorrento Therapeutics, Inc.'s tech stack includes Veeam, AutoCAD, SOLIDWORKS, Salesforce, UKG, WP Engine, New Relic and Adobe Creative Suite.

What is Sorrento Therapeutics, Inc.'s email format?

Minus sign iconPlus sign icon
Sorrento Therapeutics, Inc.'s email format typically follows the pattern of FLast@sorrentotherapeutics.com. Find more Sorrento Therapeutics, Inc. email formats with LeadIQ.

How much funding has Sorrento Therapeutics, Inc. raised to date?

Minus sign iconPlus sign icon
As of October 2026, Sorrento Therapeutics, Inc. has raised $264M in funding. The last funding round occurred on Oct 09, 2019 for $25M.

When was Sorrento Therapeutics, Inc. founded?

Minus sign iconPlus sign icon
Sorrento Therapeutics, Inc. was founded in 2009.
Sorrento Therapeutics, Inc. logo

Sorrento Therapeutics, Inc.

Biotechnology ResearchCalifornia, United States51-200 Employees

Sorrento Therapeutics, Inc. is a San Diego-based biotechnology company focused on both clinical-stage and commercial biopharmaceuticals that address unmet medical needs across cancer, autoimmune and inflammatory diseases, viral infections, and neurodegenerative conditions. It aims to develop next-generation therapeutics by combining a proprietary antibody library with targeted delivery approaches. The company pursues a broad range of modalities, including cell-based therapies, antibody-drug conjugates, oncolytic virus platforms, targeted lymphatic delivery, and bispecific antibodies, along with pain management candidates and antiviral and diagnostic programs tied to the COVID-19 response. It operates in the biotechnology research industry, focusing on delivering therapies that target significant clinical needs. A recent development includes a contract with the U.S. National Institute of Allergy and Infectious Diseases to develop a rapid testing instrument, reflecting ongoing collaboration beyond therapeutics.

Section iconCompany Overview

Phone number
SIC Code
8731 - Commercial Physical and Biological Research
Stock Symbol
SRNE
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2009
Employees
51-200

Section iconFunding & Financials

  • $264M

    Sorrento Therapeutics, Inc. has raised a total of $264M of funding over 8 rounds. Their latest funding round was raised on Oct 09, 2019 in the amount of $25M as a Post IPO Equity.

  • $50M - $100M

    Sorrento Therapeutics, Inc.'s revenue is estimated to be in the range of $50M - $100M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.